Trial Profile
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate; Salmeterol
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms TORCH
- Sponsors GlaxoSmithKline; GSK
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society.
- 24 May 2017 Results comparing patient characteristics from SLS COPD with SUMMIT, TORCH, FLAME and TRILOGY trials presented at the 113th International Conference of the American Thoracic Society
- 01 Dec 2009 Effect of treatment on prevalence and progression of osteoporosis in a subset of US patients (n=658).